What Is the CJC-1295 (No DAC) / Ipamorelin Blend?
Two peptides working two different receptors at the same time — that's the core idea behind this blend. CJC-1295 (no DAC) hits the growth hormone-releasing hormone (GHRH) receptor to drive GH synthesis, while Ipamorelin activates the ghrelin receptor (GHS-R1a) to amplify the resulting pulse. The combination produces a GH release that's both larger and more physiologically timed than either compound achieves alone.
This is one of the most commonly discussed peptide combinations in the anti-aging and hormone optimization space, which is why it shows up constantly in clinic menus and research forums. That popularity is worth understanding in context: the evidence base here is largely preclinical and practitioner-reported. There are no published randomized controlled trials on this specific blend. What exists is mechanistic research on each component separately, animal studies, and a substantial body of practitioner experience — which is meaningful but not the same thing as Phase 3 human trial data.
The 10mg designation refers to the total peptide content in a blended vial — typically 5mg of each component — formulated for reconstitution and subcutaneous injection.